A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 111
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : bDFS
Long Form : biochemical disease-free survival
No. Year Title Co-occurring Abbreviation
2022 Conventional dose versus dose escalated radiotherapy including high-dose-rate brachytherapy boost for patients with Gleason score 9-10 clinical localized prostate cancer. Conv RT, DMFS, HDR boost, HDRT, IMRT, PCSM
2022 Grade migration and important prognostic factors in a pathology specimen for radical radiotherapy in prostate cancer patients. BC
2022 Stereotactic Radiotherapy and Androgen Deprivation Therapy for Localized Prostate Cancer: A Retrospective Mono-institutional Experience. ADT, IIEF, IPSS, OS, PROs, SRT, V-MAT IGRT
2022 The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521. CRP, HR, IL, RT, RTOG
2021 Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial. DFS
2021 Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors. BT, DMSF, EBRT, PCSM, VHR
2021 Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial. ADT, HRT, MFS, OS, PCa
2021 Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy. HDR, OS, PSS
2021 Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes. IMPT, PBS, PSA
10  2020 A systematic review of salvage focal therapies for localised non-metastatic radiorecurrent prostate cancer. ADT, PSA, RP, SBT, WW
11  2019 Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial. ADT, GS, PCa, PSA, RT
12  2019 Evaluation of neutrophil-to-lymphocyte ratio as a prognostic indicator in a Singapore cohort of patients with clinically localized prostate cancer treated with prostatectomy. AUC, CSS, MFS, NLR, OS
13  2019 Impact of a dominant intraprostatic lesion (DIL) boost defined by sextant biopsy in permanent I-125 prostate implants on biochemical disease free survival (bDFS) and toxicity outcomes. DIL
14  2019 Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography. BF, LNs, PCa, PET, PSA, PSMA, SBRT
15  2019 Ultra-hypofractionated radiation therapy for unfavourable intermediate-risk and high-risk prostate cancer is safe and effective: 5-year outcomes of a phase II trial. PCa, UHRT
16  2018 Contemporary Radiation Treatment of Prostate Cancer in Africa: A Ghanaian Experience. PCa
17  2018 Non-Whole-Gland High-Intensity Focused Ultrasound vs Whole-Gland High-Intensity Focused Ultrasound for Management of Localized Prostate Cancer: 1-Year Oncological and Functional Outcomes. HIFU, IIEF-5, IPSS, mpMRI, PSA
18  2018 Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: Where are we now? BT, HDR, HR, SBRT
19  2018 Tailored postoperative treatment of prostate cancer: final results of a phase I/II trial. EORTC, HT, OS, PSA, RP, RT
20  2017 Adaptive cone-beam CT planning improves long-term biochemical disease-free survival for 125I prostate brachytherapy. BF, CBCT, CI, HR, NCCN, PCa, TRUS
21  2017 Clinical outcome and toxicity evaluation of simultaneous integrated boost pelvic IMRT/VMAT at different dose levels combined with androgen deprivation therapy in prostate cancer patients. ADT, DMFS, PTV
22  2017 Comparison on efficacy of radical prostatectomy versus external beam radiotherapy for the treatment of localized prostate cancer. CSS, EBRT, HR, IMRT, OR, OS, RP
23  2017 Effects of dose-escalated radiotherapy in combination with long-term androgen deprivation on prostate cancer. ADT, cRFS, OS, RT
24  2017 Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer. BCF, CEFS, CI, FS-HIFU, HIFU, IQR, PET, PSA, SD
25  2017 Heterogeneity of Outcomes in D'Amico Intermediate-Risk Prostate Cancer Patients after Radical Prostatectomy: Influence of Primary and Secondary Gleason Score. bGS, IR
26  2017 Impact of a rectal and bladder preparation protocol on prostate cancer outcome in patients treated with external beam radiotherapy. cDFS, GS, MVA, PCa, PCSS, UVA
27  2017 Prognostic factors in prostate cancer patients treated by radical external beam radiotherapy. cDFS, CSS, CT, GS, RT
28  2017 Studying the efficacy of escalated dose conformal radiation therapy in prostate carcinoma - Pakistan experience. EBRT, PSA
29  2017 Very high-risk prostate cancer: stratification by outcomes of radiotherapy and long-term androgen deprivation therapy. ADT, cRFS, CSS, EBRT, VHR
30  2016 External beam radiotherapy with dose escalation in 1080 prostate cancer patients: definitive outcome and dose impact. cDFS, CSOS, EBRT, GI, GS, GU
31  2016 Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature. F-CTV, GI, GU, PSA, PTV
32  2016 Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review. ---
33  2016 High-dose radiotherapy with helical tomotherapy and long-term androgen deprivation therapy for prostate cancer: 5-year outcomes. ADT, HT, IQR
34  2016 Proposal for magnetic resonance imaging-guided salvage radiotherapy for prostate cancer. CT, HR, MRI, PSA, SRT
35  2016 Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after primary radiotherapy failure. HDR-BT, OS
36  2016 Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry. GI, SBRT
37  2016 Ten-year outcomes using low dose rate brachytherapy for localised prostate cancer: An update to the first Australian experience. CTCAE, PSA
38  2015 Definitive radiotherapy plus regional hyperthermia for high-risk and very high-risk prostate carcinoma: Thermal parameters correlated with biochemical relapse-free survival. HT, RT
39  2015 Definitive radiotherapy plus regional hyperthermia for high-risk and very high-risk prostate carcinoma: Thermal parameters correlated with biochemical relapse-free survival. HT, RT
40  2015 Is modern external beam radiotherapy with androgen deprivation therapy still a viable alternative for prostate cancer in an era of robotic surgery and brachytherapy: a comparison of Australian series. ADT, DE-IG-IMRT, EBRT, HR, IR, MFS, PCaSS
41  2015 Neo-adjuvant hormone therapy for non-metastatic prostate cancer: a systematic review and meta-analysis of 5,194 patients. cDFS, CI, NHT, OR, OS, PCa, PSM, RCTs, RP
42  2015 Postoperative radiotherapy in prostate cancer: Analysis of prognostic factors in a series of 282 patients. GS, HT, PSA, RT
43  2014 Clinical implications of a prostate-specific antigen bounce after radiation therapy for prostate cancer. PSA
44  2014 External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer. ADT, DMFS, EBRT, LDR, OS
45  2014 Long-term outcomes from dose-escalated image-guided intensity-modulated radiotherapy with androgen deprivation: encouraging results for intermediate- and high-risk prostate cancer. ADT, DE, IG-IMRT, IMRT
46  2014 Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study. EPIC, SBRT
47  2014 The clinical significance of persistent cancer cells on prostate biopsy after high-dose-rate brachytherapy boost for intermediate-risk prostate cancer. PSA
48  2013 Cryoablation for locally advanced clinical stage T3 prostate cancer: a report from the Cryo-On-Line Database (COLD) Registry. ADT, COLD, cT3, EBRT, RP
49  2013 Does neoadjuvant androgen deprivation therapy before primary whole gland cryoablation of the prostate affect the outcome? CRYO, NADT
50  2013 Four-year outcomes of hypofractionated high-dose-rate prostate brachytherapy and external beam radiotherapy. BED, HDR, IMRT, PSA
51  2013 Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer. HIFU, PCa
52  2013 Intensity-modulated radiotherapy versus radical prostatectomy in patients with localized prostate cancer: long-term follow-up. CSS, IMRT, MOC, OS, PCa, PSA, RP
53  2013 May non-metastatic clinically localized castration-resistant prostate cancer after primary androgen ablation benefit from salvage prostate radiotherapy? BF, CSS, DMFS, EBRT, GS, nPSA, PADT
54  2013 Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels: a single institution analysis. ADT, CSS, DMFS, EBRT, GS, OS
55  2013 [High-intensity focussed ultrasound in low-risk prostate cancer - oncological outcome and postinterventional quality of life of an inexperienced therapy centre in comparison with an experienced therapy centre]. HIFU, PCa, TURP
56  2012 Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy. ---
57  2012 Initial brazilian experience in the treatment of localized prostate cancer using a new generation cryotechnology: feasibility study. ---
58  2012 Low-dose rate brachytherapy of the prostate in elderly patients. ASTRO, NCCN, OS, RTOG
59  2012 Outcomes of salvage prostate cryotherapy stratified by pre-treatment PSA: update from the COLD registry. COLD, PSA
60  2012 Preliminary results of intensity-modulated radiation therapy with helical tomotherapy for prostate cancer. ADT, GI, GU, HT
61  2012 Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma. BF, BRT, nPSA
62  2012 Re-irradiation for salvage of prostate cancer failures after primary radiotherapy. PSA, PSADT
63  2011 A retrospective analysis after low-dose-rate prostate brachytherapy with permanent (125)I seed implant: clinical and dosimetric results in 70 patients. ASTRO, GS, NCCN
64  2011 Effect of whole pelvic radiotherapy for patients with locally advanced prostate cancer treated with radiotherapy and long-term androgen deprivation therapy. ADT, PORT, WPRT
65  2011 Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir. ADT, OS, PCSS, PSA, RT
66  2011 High-intensity focused ultrasound as salvage therapy for patients with recurrent prostate cancer after external beam radiation, brachytherapy or proton therapy. EBRT, HIFU, PSA
67  2011 Impact of race on biochemical disease recurrence after prostate brachytherapy. ADT, EBRT, FFBF, PSA
68  2011 Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry. CI, COLD, PSA
69  2011 Prognostic impact of abdominal adiposity, waist circumference and body mass index in patients with intermediate-risk prostate cancer treated with radiotherapy. BMI, GS, nPSA, SAT, WC
70  2011 Robotic radical prostatectomy: a critical analysis of the impact on cancer control. RALP
71  2011 The pattern of prostate cancer local recurrence after radiation and salvage cryoablation. ---
72  2010 A multi-institutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy. ART, LVI, PSA, RP, RT, SM, SRT
73  2010 Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease? LTAD, PSA, STAD
74  2010 Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer. IQR, PCa, PSA
75  2010 Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer. BTV, DSS, IGRT-DE, mets, RG, SPECT/CT
76  2010 Treatment for intermediate and high-risk prostate cancer: controversial issues and the role of hyperthermia. AST, HT, OS, QoL, RT
77  2009 Definitive conformal radiotherapy for localized prostate cancer: a long-term follow-up study. AD, HR, IR, LR, OS
78  2009 Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy? ART, NADT, OS, RP, RT, SRT
79  2009 External radiotherapy for prostate cancer with or without androgen deprivation: Geneva, 1991 to 2004. AD, OS, RT
80  2009 Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study. HDR-BT
81  2009 Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial. ADT, PRPH-PSA, RT
82  2009 Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. IMRT, PSA, RP
83  2009 Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. PORT, WPRT
84  2009 [Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: comparisons among ASTRO and Phoenix biochemical failure definitions]. RT
85  2008 Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us? ASTRO, LTAD, NB, PB, PCa, PSA, RT, STAD, TRUS
86  2008 Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life. ASTRO, HRQoL, PSA, QoL
87  2007 (125)I monotherapy using D90 implant doses of 180 Gy or greater. ---
88  2007 Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide. ASTRO, BTVs, EBRT, PSA, RF, RG, SI, SPECT/CT
89  2007 Definitive conformal radiotherapy for localized high-risk prostate cancer: a long-term follow-up study with PSA course. ---
90  2007 High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy. HGPIN, PSA, RP
91  2007 Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives. AD, ASTRO, SD-EBRT
92  2007 Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer. BMI, DSS, OS, RT
93  2007 Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy. DSS, OS, PSAV
94  2007 Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer. CRYO, DSS, EBRT, GI, OS
95  2006 Dose escalation with three-dimensional conformal radiotherapy for prostate cancer. Is more dose really better in high-risk patients treated with androgen deprivation? AAD, ICRU, NAD
96  2005 Dosimetry and cancer control after low-dose-rate prostate brachytherapy. bRFS, LDR-PB
97  2005 Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation. CI, EBRT, NAHT, PSA
98  2005 Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. AAD, AD, NAD
99  2005 [Dose escalation with three dimensional conformal radiotherapy for prostate cancer: more is better?]. AAD, NAD
100  2004 Combination conformal radiotherapy and radioimmunoguided transperineal 103Pd implantation for patients with intermediate and unfavorable risk prostate adenocarcinoma. BTVs, EBRT, HT, RF